Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s.

about

Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s.

Item

http://www.wikidata.org/entity/Q40056586

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Boceprevir and Antiretroviral ...... cal Trials Group Study A5309s.

@en

type

Item

label

Boceprevir and Antiretroviral ...... cal Trials Group Study A5309s.

@en

prefLabel

Boceprevir and Antiretroviral ...... cal Trials Group Study A5309s.

@en

P1476

Boceprevir and Antiretroviral ...... cal Trials Group Study A5309s.

@en

P2093

ACTG A5309s study team

http://www.w3.org/2001/XMLSchema#string

Adeel A Butt

http://www.w3.org/2001/XMLSchema#string

Darlene Lu

http://www.w3.org/2001/XMLSchema#string

Gene D Morse

http://www.w3.org/2001/XMLSchema#string

Jennifer J Kiser

http://www.w3.org/2001/XMLSchema#string

Kenneth E Sherman

http://www.w3.org/2001/XMLSchema#string

Robin DiFrancesco

http://www.w3.org/2001/XMLSchema#string

Susan L Rosenkranz

http://www.w3.org/2001/XMLSchema#string

P2860

Boceprevir for previously treated chronic HCV genotype 1 infection

Boceprevir for untreated chronic HCV genotype 1 infection

Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.

Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir

Adding value to antiretroviral proficiency testing

Clinical pharmacology quality assurance program: models for longitudinal analysis of antiretroviral proficiency testing for international laboratories

Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.

Clinical pharmacology quality assurance for HIV and related infectious diseases research.

The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update.

Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.

P304

557-567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40268-017-0205-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28875397

http://www.w3.org/2001/XMLSchema#string

P932

5694418

http://www.w3.org/2001/XMLSchema#string